Estela Pineda

Publicaciones destacadas

• Mutational profiling allows the stratification of metastatic colorectal cancer patients with poor prognosis

  Autores: Rodriguez Hernandez, A.; LaHoz, S.; Laia, F. M.; Gorria Puga, T.; Moreno, R.; Esposito, F.; Oliveres, H.; Albiol Rodriguez, S.; Sauri, T.; Cuatrecasas, M.; Jares, P.; Pedrosa, L.; Pineda, E.; Castells, A.; Prat, A.; Camps, J.; Maurel, J.;.

  Referencia: Annals Of Oncology 2023.

• Glioblastoma TCGA mesenchymal and IGS 23 tumors are identifiable by immunohistochemistry and have an immune-phenotype indicating potential benefit from immunotherapy

  Autores: Carrato C, Alameda F, Esteve-Codina A, Pineda E, Arpí O, Martinez-García M, Mallo M, Gut M, Lopez-Martos R, Barco SD, Ribalta T, Capellades J, Puig J, Gallego O, Mesia C, Muñoz-Marmol AM, Archilla I, Arumí M, Blanc JM, Bellosillo B, Menendez S, Esteve A, Bagué S, Hernandez A, Craven-Bartle J, Fuentes R, Vidal N, Aldecoa I, Iglesia N, Balana C .

  Referencia: Clinical Cancer Research 2020.

• A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond six cycles in patients with glioblastoma (GEINO 14-01)

  Autores: Balana C, Vaz MA, Manuel Sepúlveda J, Mesia C, Del Barco S, Pineda E, Muñoz-Langa J, Estival A, de Las Peñas R, Fuster J, Gironés R, Navarro LM, Gil-Gil M, Alonso M, Herrero A, Peralta S, Olier C, Perez-Segura P, Covela M, Martinez-García M, Berrocal A, Gallego O, Luque R, Perez-Martín FJ, Esteve A, Munne N, Domenech M, Villa S, Sanz C, Carrato C .

  Referencia: Neuro-Oncology 2020.

• Phase II Trial of Palbociclib in Recurrent Retinoblastoma-Positive Anaplastic Oligodendroglioma: A Study from the Spanish Group for Research in Neuro-Oncology (GEINO)

  Autores: Sepúlveda-Sánchez JM; Gil-Gil M; Alonso-García M; Vaz Salgado MÁ; Vicente E; Mesía Barroso C; Rodríguez Sánchez Á; Durán G; De Las Peñas R; Muñoz-Langa J; Velasco G; Hernández-Laín A; Hilario A; Navarro Martín M; Benavides M; Oleaga L; Cantero Montenegro D; Ruano Y; Sánchez-Gómez P; Martín-Soberón MC; Morales-Llombart R; Pachón V; Pineda E.

  Referencia: Targeted Oncology 2020.

• Buparlisib plus carboplatin or lomustine in patients with recurrent glioblastoma: a phase Ib/II, open-label, multicentre, randomised study

  Autores: Rosenthal M; Clement PM; Campone M; Gil-Gil MJ; DeGroot J; Chinot O; Idbaih A; Gan H; Raizer J; Wen PY; Pineda E; Donnet V; Mills D; El-Hashimy M; Mason W.

  Referencia: Esmo Open 2020.

• MET inhibitors in cancer: pitfalls and challenges

  Autores: Oliveres, Helena; Pineda, Estela; Maurel, Joan;.

  Referencia: Expert Opinion On Investigational Drugs 2020.

• LIF regulates CXCL9 in tumor-associated macrophages and prevents CD8+ T cell tumor-infiltration impairing anti-PD1 therapy

  Autores: Pascual-García M., Bonfill-Teixidor E., Planas-Rigol E., Rubio-Perez C., Iurlaro R., Arias A., Cuartas I., Sala-Hojman A., Escudero L., Martínez-Ricarte F., Huber-Ruano I., Nuciforo P., Pedrosa L., Marques C., Braña I., Garralda E., Vieito M., Squatrito M., Pineda E., Graus F., Espejo C., Sahuquillo J., Tabernero J., Seoane J..

  Referencia: Nature Communications 2019.

• Randomized phase IIb clinical trial of continuation or non-continuation with six cycles of temozolomide after the first six cycles of standard first-line treatment in patients with glioblastoma: A Spanish research group in neuro-oncology (GEINO) trial.

  Autores: Balana, Carmen; Mesia Barroso, Carlos; Del Barco Berron, Sonia; Pineda Losada, Estela; Munoz-Langa, Jose; Estival, Anna; De las Penas, Ramon; Fuster, Jose; Gil Gil, Miguel J.; Miguel Navarro, L.; Alonso, Miriam; Herrero, Ana; Vaz Salgado, Maria Angeles; Peralta, Sergi; Olier, Clara; Perez-Segura, Pedro; Covela Rua, Marta; Carrato, Cristina; Sanz, Carolina; Manuel Sepulveda-Sanchez, Juan;.

  Referencia: Journal Of Clinical Oncology 2019.

• COULD SUSPECTED GLIOBLASTOMAS BE TREATED WITHOUT HYSTOLOGICAL DIAGNOSIS?

  Autores: Cortes Mateus, K.; Valduvieco Ruiz, I.; Verger Fransoy, E.; Pineda Losada, E.; Oleaga Zufiria, L.; Pujol Farre, T.; Gonzalez Sanchez, J.; Pedrosa Eguilaz, L.; Ribas, F. Graus; Barreto Zambrano, T.; Munoz Guglielmetti, D.; Castro Cuevas, C.; Escudero Lopez, E.; Lloret Puerto, A.; Saez Beltran, J.; Camacho Lopez, C.; Conill Llobet, C.; Oses Gonzalez, G.; Garrido Alcantud, S.; Molla Armada, M.;.

  Referencia: Neuro-Oncology 2019.

• Predictive serum biomarkers in metastatic colorectal cancer patients treated in the BECOX trial with oxaliplatin-capecitabine (CAPOX) plus bevacizumab (GEMCAD 09-01)

  Autores: Pineda Losada, E.; Salud, A.; Vila-Navarro, E.; Safont, M. J.; Garcia-Giron, C.; Aparicio, J.; Vera, R.; Escudero, M. P.; Casado, E.; Bosch, C.; Bohn, U.; Perez Carrion, R. M.; Carmona Bayonas, A.; Ayuso, J. R.; Ripolles, T.; Bouzas, R.; Gironella, M.; Garcia-Albeniz, X.; Feliu, J.; Maurel, J.;.

  Referencia: European Journal Of Cancer 2015.